Migraine – Introduction

by | Last updated Nov 20, 2017 | Published on Nov 14, 2014 | Anti-Depressants, Other |

Some of you will know it has been my view for some time that the association between migraine and depression is closer than has generally been recognised. Evidence is now accumulating that this covers the genetics, pathophysiology and treatment of these two conditions.

The fact that both are common conditions does mean chance associations will be relatively common. Two epidemiological studies have both come up with similar statistics for an association between migraine, anxiety, and depression. That association is greater than can be explained by chance.

Merikangas’ prospective study suggests that for Migraineurs the lifetime course in 80% of cases is that anxiety precedes migraine, and in 75% depression succeeds migraine. A second large (but retro-spective) study produced reassuringly similar figures. Suicide attempt rates in migraineurs without depression were slightly elevated (7.1% vs 2.2% in controls); in migraine plus depression suicide attempt rate was high at 31.8%. This compared to depression alone at 16.5%.

Recent genetic studies further substantiate an association. These originate from Steven Peroutka who with Solomon Snyder just lost the race to ‘discover’ endorphins (to Hughes and Kosterlitz) and who then went on to become a leading world figure in 5-HT receptor sub-typing.

Their recent paper (Peroutka, S) about the genetics of depression and migraine concludes:–
‘These data indicate that migraine with aura, anxiety disorders, and major depression can be components of a distinct clinical syndrome associated with allelic variations within the DRD2 gene. Clinical recognition of this genetically based syndrome has significant diagnostic and therapeutic implications’.

This evidence suggests the wisdom of looking carefully for depressive symptoms in all those with migraine; it is logical that treatment decisions will be strongly influenced by co-morbidity.

Migraineurs without diagnosed depression may still have an increased risk of suicide.

When patients manifest both depression and migraine it is important to treat both conditions. It is useful to screen migraineurs for both past and family history of depression (especially bipolar disorder) and panic attacks. This will guide treatment. The association of migraine with bipolar disorder will influence antidepressant choice. for instance, Epilim may be considered for possible or definite bipolar cases.

This is a common problem and a fascinating area of therapeutics; it will reward your efforts with many grateful patients.

12.       Meyer, JH, Goulding, VS, Wilson, AA, Hussey, D, et al., Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology, 2002. 163(1): p. 102-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12185406

13.       Learned-Coughlin, SM, Bergstrom, M, Savitcheva, I, Ascher, J, et al., In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry, 2003. 54(8): p. 800-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14550679

14.       Argyelan, M, Szabo, Z, Kanyo, B, Tanacs, A, et al., Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord, 2005. 89(1-3): p. 115-23.

https://www.ncbi.nlm.nih.gov/pubmed/16213028

15.       Volkow, ND, Wang, GJ, Fowler, JS, Learned-Coughlin, S, et al., The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry, 2005. 57(6): p. 640-6.

https://www.ncbi.nlm.nih.gov/pubmed/15780851

16.       Owens, JM, Knight, DL, and Nemeroff, CB, [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine]. Encephale, 2002. 28(4): p. 350-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12232544

17.       Yohn, SE, Collins, SL, Contreras-Mora, HM, Errante, EL, et al., Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior. Neuropsychopharmacology, 2016. 41(3): p. 686-94.

https://www.ncbi.nlm.nih.gov/pubmed/26105139

18.       Ascher, JA, Cole, JO, Colin, JN, Feighner, JP, et al., Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry, 1995. 56(9): p. 395-401.

19.       Carroll, FI, Blough, BE, Mascarella, SW, Navarro, HA, et al., Bupropion and bupropion analogs as treatments for CNS disorders. Adv. Pharmacol., 2014. 69: p. 177-216.

https://www.ncbi.nlm.nih.gov/pubmed/24484978

20.       Gufford, BT, Lu, JB, Metzger, IF, Jones, DR, et al., Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo. Drug Metab. Dispos., 2016. 44(4): p. 544-53.

https://www.ncbi.nlm.nih.gov/pubmed/26802129

21.       Benowitz, NL, Zhu, AZ, Tyndale, RF, Dempsey, D, et al., Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics, 2013. 23(3): p. 135-41.

https://www.ncbi.nlm.nih.gov/pubmed/23344581

22.       Talakad, JC, Kumar, S, and Halpert, JR, Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab. Dispos., 2009. 37(3): p. 644-50.

https://www.ncbi.nlm.nih.gov/pubmed/19074527

23.       Molnari, JC, Hassan, HE, and Myers, AL, Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice. Eur. J. Drug Metab. Pharmacokinet., 2012. 37(1): p. 57-63.

https://www.ncbi.nlm.nih.gov/pubmed/21928040

24.       Hoiseth, G, Haslemo, T, Uthus, LH, and Molden, E, Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data. Ther. Drug Monit., 2015. 37(5): p. 589-93.

https://www.ncbi.nlm.nih.gov/pubmed/25565674

25.       Laib, AK, Brunen, S, Pfeifer, P, Vincent, P, et al., Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. Ther. Drug Monit., 2014. 36(4): p. 473-9.

https://www.ncbi.nlm.nih.gov/pubmed/24452068

26.       Al-Abri, SA, Orengo, JP, Hayashi, S, Thoren, KL, et al., Delayed bupropion cardiotoxicity associated with elevated serum concentrations of bupropion but not hydroxybupropion. Clin Toxicol (Phila), 2013. 51(10): p. 1230-4.

https://www.ncbi.nlm.nih.gov/pubmed/24131328

27.       Hayes, PE and Kristoff, CA, Adverse reactions to five new antidepressants. Clin. Pharm., 1986. 5(6): p. 471-80.

https://www.ncbi.nlm.nih.gov/pubmed/3087684

28.       Balit, CR, Lynch, CN, and Isbister, GK, Bupropion poisoning: a case series. Med. J. Aust., 2003. 178(2): p. 61-3.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12526723

29.       Salamone, JD, Pardo, M, Yohn, SE, Lopez-Cruz, L, et al., Mesolimbic Dopamine and the Regulation of Motivated Behavior. Curr Top Behav Neurosci, 2016. 27: p. 231-57.

https://www.ncbi.nlm.nih.gov/pubmed/26323245

30.       Salamone, JD and Correa, M, The mysterious motivational functions of mesolimbic dopamine. Neuron, 2012. 76(3): p. 470-85.

https://www.ncbi.nlm.nih.gov/pubmed/23141060

31.       Floresco, SB, Tse, MT, and Ghods-Sharifi, S, Dopaminergic and glutamatergic regulation of effort- and delay-based decision making. Neuropsychopharmacology, 2008. 33(8): p. 1966-79.

https://www.ncbi.nlm.nih.gov/pubmed/17805307

32.       Randall, PA, Pardo, M, Nunes, EJ, Lopez Cruz, L, et al., Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences. PLoS One, 2012. 7(10): p. e47934.

https://www.ncbi.nlm.nih.gov/pubmed/23110135

33.       Hosking, JG, Floresco, SB, and Winstanley, CA, Dopamine antagonism decreases willingness to expend physical, but not cognitive, effort: a comparison of two rodent cost/benefit decision-making tasks. Neuropsychopharmacology, 2015. 40(4): p. 1005-15.

https://www.ncbi.nlm.nih.gov/pubmed/25328051

34.       Mai, B, Sommer, S, and Hauber, W, Motivational states influence effort-based decision making in rats: the role of dopamine in the nucleus accumbens. Cogn Affect Behav Neurosci, 2012. 12(1): p. 74-84.

https://www.ncbi.nlm.nih.gov/pubmed/22012275

35.       Yohn, SE, Errante, EE, Rosenbloom-Snow, A, Somerville, M, et al., Blockade of uptake for dopamine, but not norepinephrine or 5-HT, increases selection of high effort instrumental activity: Implications for treatment of effort-related motivational symptoms in psychopathology. Neuropharmacology, 2016. 109: p. 270-80.

https://www.ncbi.nlm.nih.gov/pubmed/27329556

36.       Yohn, SE, Gogoj, A, Haque, A, Lopez-Cruz, L, et al., Evaluation of the effort-related motivational effects of the novel dopamine uptake inhibitor PRX-14040. Pharmacol. Biochem. Behav., 2016. 148: p. 84-91.

https://www.ncbi.nlm.nih.gov/pubmed/27296079

37.       Frank, S, Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat, 2010. 6: p. 657-65.

https://www.ncbi.nlm.nih.gov/pubmed/20957126

38.       Jankovic, J and Orman, J, Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology, 1988. 38(3): p. 391-4.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3279337

39.       Kenney, C, Hunter, C, Mejia, N, and Jankovic, J, Is history of depression a contraindication to treatment with tetrabenazine? Clin. Neuropharmacol., 2006. 29(5): p. 259-64.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16960470

40.       Kenney, C, Hunter, C, and Jankovic, J, Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov. Disord., 2007. 22(2): p. 193-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17133512

41.       Baumeister, AA, Hawkins, MF, and Uzelac, SM, The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J Hist Neurosci, 2003. 12(2): p. 207-20.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12953623

42.       van Praag, H, Asnis, GM, Kahn, RS, Brown, SL, et al., Monoamines and Abnormal Behaviour.  A Multi-Aminergic Perspective. Br J Psychiatry, 1990. 157: p. 723-734.

43.       van Praag, HM, Nosologomania: a disorder of psychiatry. World J Biol Psychiatry, 2000. 1(3): p. 151-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12607225

PsychoTropical is entirely dependent on donations to function. If you have gained useful value from this, then you should consider a donation. Visit the Donate page.

Pin It on Pinterest

Share This

Share this post and spread the word